Victoria Sluzky, Ph.D. is the Chief Technology Officer (CTO) at Elektrofi Inc., an early-stage company developing protein formulations which enable subcutaneous administration of ultra-high concentrations of biotherapeutics. She is also the Founder and Principal at Lucid Biotechnology Advisors LLC, a strategic consultancy for emerging biotechnology companies. Specializing in quality, manufacturing, and pharmaceutical development of gene therapy and biologic therapeutics, Dr. Sluzky has more than 30 years of healthcare and biotechnology experience, including 19 years at BioMarin Pharmaceutical, where she served as Senior Vice President of Technical Development. Dr. Sluzky’s earlier roles in biotechnology focused on leading analytical and formulation development groups at Onyx Pharmaceutical, COR Therapeutics and Scios. Her broad range of experience includes design and optimization of analytical methods; formulation of parenteral and solid dosage forms; process development and technology transfer; quality control, quality assurance and compliance programs; and regulatory strategy. She contributed to the approval of nine commercial products including ROCTAVIAN™, Voxzogo®, Palynziq®, Brineura®, Vimizim®, Kuvan®, Naglazyme®, Aldurazyme® and Integrilin® .
Victoria holds a Ph.D. in Chemical Engineering from Massachusetts Institute of Technology and a Bachelor of Science in Chemical Engineering from Stanford University. She is a Fellow of American Institute of Medical and Biological Engineers, a non-profit organization headquartered in Washington, D.C., representing the most accomplished individuals in the fields of medical and biological engineering.